Menu
Recruiting NCT07241104

A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy

Phase I Interventional Dilated Cardiomyopathy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: AZD4063.
Who it may be relevant to
Registry conditions: Dilated Cardiomyopathy. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Netherlands
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Phase I First-in-human Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD4063 in Adults With Phospholamban R14del Dilated Cardiomyopathy

Overview

The purpose of the study is to assess the safety, tolerability and the pharmacokinetics (PK) of AZD4063 after single and multiple dose administration in participants with phospholamban (PLN) R14del dilated cardiomyopathy.

Detailed description

This is a Phase 1, first in human, unblinded, ascending dose study which will be comprised of: 3 single ascending dose (SAD) cohorts, 3 multiple ascending dose (MAD) cohorts and optional cohorts.

The SAD part of the study will assess the single doses of AZD4063 across 3 cohorts. It will consist of:

* A screening period * A treatment period: The participants will receive a single dose of AZD4063 by subcutaneous (SC) injection * A follow-up period

The MAD part of the study will initiate on receiving the data from SAD cohort with available safety, PK and pharmacodynamics (PD) data from all cohorts. This part of the study will consist of:

* A screening period * A treatment period: The participants will receive multiple doses of AZD4063 by SC injection * A follow-up period

Optional cohorts may be added based on emerging safety, PK and PD data of the SAD and MAD cohorts.

Interventions

  • Drug AZD4063
    AZD4063 will be administered in the SAD and MAD part of the study as solution for injection via subcutaneous route of administration.

Primary outcome measures

  • Number of participants with adverse events (AEs) [Time frame: Cohort 1 (SAD): From Day 1 to Day 109, Cohorts 2 and 3 (SAD) From Day 1 to Day 99; For Cohorts 1,2 and 3 (MAD): Day 1 to Day 155]
Secondary outcome measures (7)
  • Area under plasma concentration-time curve from 0 to infinity (AUCinf) [Time frame: Cohort 1 (SAD): Up to Day 95, Cohorts 2 and 3 (SAD): Up to Day 85; Cohorts 1,2,3 (MAD): Up to Day 141]
  • Area under the plasma concentration-curve from 0 to the last quantifiable concentration (AUClast) [Time frame: Cohort 1 (SAD): Up to Day 95, Cohorts 2 and 3 (SAD): Up to Day 85; Cohorts 1,2,3 (MAD): Up to Day 141]
  • Maximum plasma drug concentration (Cmax) [Time frame: Cohort 1 (SAD): Up to Day 95, Cohorts 2 and 3 (SAD): Up to Day 85; Cohorts 1,2,3 (MAD): Up to Day 141]
  • Renal clearance (CLR) [Time frame: Cohort 1 (SAD): Up to Day 95, Cohorts 2 and 3 (SAD): Up to Day 85; Cohorts 1,2,3 (MAD): Up to Day 141]
  • Cumulative amount of analyte excreted (Ae) [Time frame: Cohort 1 (SAD): Up to Day 95, Cohorts 2 and 3 (SAD): Up to Day 85; Cohorts 1,2,3 (MAD): Up to Day 141]
  • Fraction of dose excreted unchanged in urine (Fe) [Time frame: Cohort 1 (SAD): Up to Day 95, Cohorts 2 and 3 (SAD): Up to Day 85; Cohorts 1,2,3 (MAD): Up to Day 141]
  • Change in endomyocardial biopsy PLN messenger ribonucleic acid (mRNA levels) from baseline to estimated peak knockdown and estimated return-to-baseline [Time frame: Cohort 1 (SAD): Up to Day 95, Cohorts 2 and 3 (SAD): Up to Day 85; Cohorts 1,2,3 (MAD): Up to Day 141]

Eligibility criteria

Inclusion criteria

  • Participants must be 18 to 80 years of age inclusive, at the time of Screening
  • Participants with pre-existing positive screening for R14 del PLN mutation
  • Participants with screening Left ventricular eject fraction ≤ 45% as assessed by echocardiography
  • Participants with New York Heart Association (NYHA) function class I-III
  • Participants on stable medical therapy for at least 6 weeks prior to Screening and during the Screening period, with no significant improvement in heart failure
  • Participants with implantable cardioverter-defibrillator (ICD) or Cardiac resynchronization therapy device (CRT-D)
  • Participants with Body mass index (BMI) within the range 18-35 kg/m2
  • Females of childbearing potential must not be lactating, and if heterosexually active must agree to use an approved method of highly effective contraception
  • All females must have a negative pregnancy test at the Screening Visit.

Exclusion criteria

  • Participants with positive hepatitis C antibody, hepatitis B virus surface antigen or hepatitis B virus core antibody
  • Known to have tested positive for Human immunodeficiency virus (HIV)
  • Any known genetic mutation associated with hereditary electrical or structural disease
  • Congenital long QT syndrome
  • QTcF < 350 ms
  • Known Short QT syndrome (SQTS) or family history of SQTS
  • Catecholaminergic polymorphic ventricular tachycardia (CPVT as calcium ion channelopathy) and recent hospitalization for heart failure or significant ventricular arrhythmia within 3 months
  • Participants with sustained ventricular arrhythmia requiring treatment and considered clinically not stable by the Investigator
  • History of subendocardial Late Gadolinium Enhancement (LGE) suggestive of previous myocardial infarction and/or significant coronary artery disease (50% > stenosis in one major epicardial coronary artery or need for previous percutaneous coronary intervention or coronary artery bypass grafting)
  • Routinely scheduled outpatient intravenous infusions for heart failure
  • Uncontrolled hypertension
  • Significant primary valvular disease
  • Congenital heart disease
  • Left ventricular wall thickness of > 13 mm or with any relative with hypertrophic cardiomyopathy (HCM)
  • Recent acute presentation of myocarditis
  • Restrictive or peripartum cardiomyopathy; infiltrative disorders (sarcoidosis)
  • Alcohol consumption in excess
  • Any laboratory values with the following deviations:
  • Alanine Transaminase >2 upper normal limit (ULN)
  • Aspartate Transaminase >2 ULN
  • Total bilirubin > 2 x ULN
  • Estimated GFR < 30 mL/min/1.73 m2
  • Hemoglobin <10g/dL
  • Any vital sign values with the following deviations at Screening
  • Systolic blood pressure > 160 mmHg
  • Diastolic blood pressure > 100 mmHg
  • Pulse rate > 100 beats per minute
  • Toxin exposure, systemic disease known to cause Dilated Cardiomyopathy (DCM)
  • History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity
  • Any history of cardiotoxic drug exposure with documented cardiomyopathy
  • Noncardiac condition that limits expected lifespan to less than 1 year
  • Participation in another clinical study with a study intervention administered in the last 3 months
  • Participants with a known hypersensitivity to AZD4063
  • Participants who are part of a gene therapy trial

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Non-randomized
Model
Sequential
Masking
Open label
Primary purpose
Treatment

Study locations

Netherlands · 4 centers
  • Research Site — Amsterdam
  • Research Site — Groningen
  • Research Site — Rotterdam
  • Research Site — Utrecht

Identifiers

NCT: NCT07241104 · D8340C00001

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗